Related Experiment Videos
Immunologic therapy for secondary and primary progressive multiple sclerosis.
1Multiple Sclerosis Research Center, University of California, Los Angeles, 710 Westwood Plaza, Los Angeles, CA 90095-1769, USA. lmyers@ucla.edu
Current Neurology and Neuroscience Reports
|March 20, 2002
Summary
Multiple sclerosis (MS) treatments target immune inflammation but do not halt progressive neurologic decline. Further research is crucial for effective progressive MS therapies, avoiding unproven regimens.
Area of Science:
- Neuroimmunology
- Neurology
Background:
- Multiple sclerosis (MS) is an immune-mediated demyelinating disease.
- MS commonly presents with a relapsing-remitting course, often progressing to secondary progressive MS.
- Primary progressive MS involves gradual worsening from onset.
Purpose of the Study:
- To review the current understanding of MS pathology, particularly axonal injury and neuronal degeneration in progressive MS.
- To evaluate the efficacy of existing immunosuppressive and immunomodulatory treatments for progressive MS.
- To highlight the need for rigorous clinical trials for new progressive MS therapies.
Main Methods:
- Review of recent pathologic studies on MS.
- Analysis of results from clinical trials of MS treatments.
- Discussion of therapeutic approaches for progressive MS.
Main Results:
- Axonal injury and neuronal degeneration are significant contributors to progressive neurologic decline in MS.
- Current MS treatments effectively reduce relapse rates but do not stop disease progression.
- No proven therapies currently exist to halt or reverse progressive MS.
Conclusions:
- Progressive neurologic decline in MS is linked to axonal damage, not just inflammation.
- Effective treatments for progressive MS are lacking.
- Well-designed clinical trials are essential to evaluate new therapies, while unproven treatments should be avoided.